drug_type
RELEVANT_DRUG
intervention_type
Biological (antibody–drug conjugate)
drug_description
Anti-BCMA antibody–drug conjugate: a humanized, afucosylated IgG1 monoclonal antibody targeting BCMA linked to the microtubule inhibitor MMAF; induces apoptosis upon internalization and leverages Fc-mediated ADCC/ADCP to deplete plasmablasts/plasma cells and reduce pathogenic autoantibodies.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
belantamab mafodotin
drug_category
ANTIBODY DRUG CONJUGATE
drug_class
Conjugate
drug_delivery_route
Intravenous
drug_mechanism_of_action
Humanized, afucosylated anti-BCMA IgG1 linked to the microtubule inhibitor MMAF. Binds BCMA on plasmablasts/plasma cells, is internalized, and releases MMAF to disrupt microtubules and induce apoptosis. Afucosylated Fc enhances FcγR engagement to drive ADCC/ADCP, depleting BCMA+ antibody-secreting cells and reducing pathogenic autoantibodies.
drug_name
Belantamab mafodotin (GSK2857914)
nct_id_drug_ref
NCT06413511